Current Report Filing (8-k)
July 26 2016 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): July 25, 2016
CELGENE CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34912
|
22-2711928
|
(State
or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
86 Morris Avenue, Summit, New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (908) 673-9000
(Former name or
former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 OTHER EVENTS
On July 25, 2016,
Celgene Corporation issued a press release providing an update on the phase III ‘REMARC’ study of REVLIMID
®
maintenance treatment in patients with diffuse large b-cell lymphoma responding to first-line r-chop therapy. Attached hereto and
incorporated herein by reference as Exhibit 99.1 is the press release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 – Press Release dated July
25, 2016
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CELGENE CORPORATION
|
|
|
|
Date: July 25, 2016
|
By:
|
/s/ Peter N. Kellogg
|
|
|
Peter N. Kellogg
|
|
|
Executive Vice President and
|
|
|
Chief Financial Officer
|
|
|
(principal financial and accounting officer)
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release dated July 25, 2016
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024